[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"liver-fat\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:liver-fat":201},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,71,95,122,149,177],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":44,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":70},"100526751",false,"NCT06138821","Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial","Effect of Endoscopic Sleeve Gastroplasty on Patients With Obesity and Concomitant Metabolic Dysfunction-Associated Steatohepatitis (MASH): A Multicenter, Open-label, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 (male or female)\n2. BMI ≥30 kg\u002Fm2 or ≥27 kg\u002Fm2 with at least one obesity-related comorbidity\n3. Self-reported stable weight (no weight change \\>5%) for 6 months prior to the first study visit\n4. Willingness to follow protocol requirements, including signed informed consent, routine follow-up schedule, completing laboratory\u002Fimaging\u002Fadditional tests, and completing diet counseling\n5. Willingness to NOT start a new anti-obesity medication for the following 12 months\n6. Residing within a reasonable distance from the investigator's office and able to travel to the investigator to complete routine follow-up visits\n7. Ability to give informed consent\n8. Women of childbearing potential (i.e., not post-menopausal, nor surgically sterilized) must agree to use adequate birth control methods\n\nExclusion Criteria:\n\n1. Known history of other chronic liver diseases (viral hepatitis, autoimmune hepatitis, drug-induced hepatitis, and genetic)\n2. Treatment with vitamin E (at doses ≥800 IU\u002Fday), pioglitazone, obeticholic acid, or resmetirom \\\u003C90 days before the first study visit\n3. History of foregut or gastrointestinal (GI) surgery (except uncomplicated fundoplication, cholecystectomy or appendectomy)\n4. Prior bariatric surgery\n5. Prior endoscopic sleeve gastroplasty\n6. Any inflammatory disease of the GI tract, including severe (LA Grade C or D) esophagitis, Barrett's esophagus with dysplasia, gastric ulceration, duodenal ulceration, cancer or specific inflammation such as Crohn's disease\n7. Potential upper gastrointestinal bleeding conditions such as esophageal or gastric varices, congenital or acquired intestinal telangiectasis, or other congenital anomalies of the gastrointestinal tract such as atresias or stenoses\n8. Severe gastroesophageal reflux disease (GERD)\n9. A structural abnormality in the esophagus or pharynx, such as a stricture or diverticulum, that could impede passage of the endoscope.\n10. Achalasia or any other severe esophageal motility disorder\n11. Chronic abdominal pain\n12. Gastroparesis or intractable constipation\n13. Hepatic insufficiency or cirrhosis\n14. Severe coagulopathy\n15. Insulin-dependent diabetes (either type 1 or type 2) or a significant likelihood of requiring insulin treatment in the following 12 months or HgbA1C ≥ 12%\n16. Patients on an anti-platelet agent, anticoagulant agent or chronic\u002Froutine use of NSAIDs\n17. Patients on corticosteroids, immunosuppressants, or narcotics\n18. Patients on an anti-seizure or anti-arrhythmic medication\n19. Patients who are pregnant or breastfeeding\n20. Excessive alcohol consumption (\\>20 g per day for women; \\>30 g per day for men)\n21. Active smoking\n22. History of poorly controlled hypertension, coronary artery disease, congestive heart failure, cardiac arrhythmia\n23. History of respiratory diseases such as chronic obstructive pulmonary disease (COPD) requiring steroids, pneumonia, or cancer\n24. History of autoimmune connective tissue disorder such as lupus, scleroderma or immunocompromised disease\n25. History of active malignancy\n26. History of genetic or hormonal causes for obesity, such as Prader Willi syndrome\n27. History of endocrine disorders affecting weight, such as uncontrolled hypothyroidism\n28. Eating disorders, including night eating syndrome, bulimia, binge eating disorder or compulsive overeating\n29. Active psychological issues preventing participation in a lifestyle modification program as determined by a psychologist","ALL","18 Years",{"count":18,"type":19},132,"ESTIMATED","INTERVENTIONAL",[22],"NA","Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease globally. While weight loss through lifestyle modification is the standard treatment, most patients regain weight limiting ultimate improvement in liver disease. On the other end of the spectrum, bariatric surgery has shown promise in the treatment of MASLD\u002Fmetabolic dysfunction-associated steatohepatitis (MASH) due to its efficacy in inducing weight loss. Nevertheless, its adoption has been hindered by the perceived invasiveness of surgery.\n\nOver the past decade, endoscopic sleeve gastroplasty (ESG) has gained recognition as a promising minimally-invasive approach to weight loss. The procedure involves utilizing a Food and Drug Administration (FDA)-authorized endoscopic suturing device to reduce the gastric volume by 70%. Studies reveal that ESG is associated with approximately 18.2% weight loss at one year after the procedure, with sustained results for at least 10 years. Nevertheless, the effect of ESG on MASH remains unknown.\n\nIn this study, the investigators will compare ESG + lifestyle modification versus lifestyle modification alone in treating histologic MASH. The study will randomize patients to one of two different treatment options: ESG + lifestyle modification or lifestyle modification alone.",[25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"Obesity","Liver Diseases","Liver Fibrosis","Liver Fat","Metabolic Dysfunction-Associated Steatotic Liver Disease","Metabolic Dysfunction-Associated Steatohepatitis","MASLD","MASH","Weight Loss","Insulin Resistance","Insulin Sensitivity","Insulin Sensitivity\u002FResistance","Metabolic Disease","Diabetes","Diabetes Mellitus, Type 2","NASH With Fibrosis","Non-Alcoholic Fatty Liver Disease","Non Alcoholic Fatty Liver","Non-alcoholic Steatohepatitis",[45,46,47,48,49,50,51,52,53,54,55,56,57],"Gut Hormones","Endoscopic Bariatric and Metabolic Therapy (EBMT)","Intragastric Balloon (IGB)","Endoscopic Suturing","Endoscopic Sleeve Gastroplasty (ESG)","Weight Management","Endoscopic Gastric Remodeling (EGR)","Endoscopic Bariatric Therapy (EBT)","Fatty Liver","Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","Metabolic Dysfunction-Associated Steatohepatitis (MASH)","Non-Alcoholic Fatty Liver Disease (NAFLD)","Non-Alcoholic Steatohepatitis (NASH)","RECRUITING","2026-06-23",{"date":61,"type":62},"2026-06-25","ACTUAL",{"date":64,"type":62},"2025-06-24",{"date":66,"type":19},"2028-06",{"name":68,"class":69},"Pichamol Jirapinyo, MD, MPH","OTHER",2,{"id":72,"slug":4,"hasResults":10,"nctId":73,"briefTitle":74,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":15,"minAge":77,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":94},"100461885","NCT05294471","Fully Automated High-Throughput Quantitative MRI of the Liver","Eligibility Criteria for Substudies 1, 2, 4, 5\n\nInclusion Criteria:\n\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n\nEligibility Criteria for Substudy 3\n\nInclusion Criteria:\n\n* Age 7 years or older\n* One of:\n\n  * Known or suspected liver iron overload\n  * Known or suspected elevated liver fat\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The subject has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n\nEligibility Criteria for Substudy 6\n\nInclusion Criteria:\n\n* Age 7 years or older\n* Scheduled for a clinical abdominal MRI exam\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Sedation required for MRI\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)",true,"7 Years",{"count":79,"type":19},200,"OBSERVATIONAL","The purpose of this research is to see if a new automated magnetic resonance imaging (MRI) method will be able to improve the images taken of the liver. Participants will have either known or suspected liver disease, known or suspected iron overload syndrome, or be a healthy adult. Participants will be in the research study for one day.",[83,84,28],"Healthy","Iron Overload","2026-03-09",{"date":87,"type":62},"2026-03-12",{"date":89,"type":62},"2023-10-16",{"date":91,"type":19},"2026-09",{"name":93,"class":69},"University of Wisconsin, Madison",1,{"id":96,"slug":4,"hasResults":10,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":20,"phases":103,"briefSummary":104,"conditions":105,"keywords":108,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":94},"100431516","NCT04899102","Intermittent Fasting for NAFLD in Adults","Pilot Study of Time-Restricted, Intermittent Fasting for Non-Alcoholic Fatty Liver Disease in Non-Obese Adults","Inclusion Criteria:\n\n1. Willing and able to provide informed consent\n2. Age 18 years or older at time of consent\n3. BMI 23-30kg\u002Fm\\^2 at screening\n4. Evidence of NAFLD confirmed by historical procedure obtained no more than 6 months prior to the screening visit, defined as:\n\n   * Grade \\>=1 steatosis on clinical liver biopsy; OR\n   * Fatty liver on validated imaging modality (non-contrast CT scan, MR Spectroscopy, MRI proton density fat fraction, ultrasound)\n5. Liver fat fraction ≥10% on H-MRS performed during the screening period\n6. Hepatitis C antibody and Hepatitis B surface antigen negative at screening\n\nExclusion Criteria:\n\n1. Heavy alcohol use for at least 3 consecutive months within the past 5 years prior to screening \\[heavy alcohol consumption is defined as: \\> 20g daily for women or \\> 30mg daily for men, assessed by the Lifetime Drinking History assessment at screening (23, 24)\\].\n2. Evidence of other known forms of chronic liver disease including:\n\n   • Alcoholic liver disease, hepatitis B, hepatitis C, PBC, PSC, autoimmune hepatitis, Wilson disease, iron overload, alpha-1-antitrypsin deficiency, drug-induced liver injury, known or suspected hepatocellular carcinoma (HCC).\n3. Current or prior history of Type II Diabetes requiring insulin or sulfonylureas due to risk of hypoglycemia with fasting.\n4. Use of any pharmacological treatments for NAFLD\u002FNASH within the 6 months prior to the screening visit, except vitamin E. Patients on a stable dose of vitamin E can be enrolled in the study.\n5. Unstable body weight \\[defined as: \\>10% reduction in body weight in the 6 months prior to the screening visit\\]\n6. Known cirrhosis, stage 4 fibrosis on prior liver biopsy, or clinical evidence of cirrhosis or portal hypertension on imaging or exam.\n7. Current or prior history of Child-Pugh score ≥7.\n8. History of liver transplant, or current placement on a liver transplant list.\n9. Known positivity for human immunodeficiency virus infection.\n10. Prior or planned bariatric surgery, patients on active pharmacological treatment for weight loss, or active involvement in a weight loss program.\n11. Routine MRI exclusion criteria, such as the presence of a pacemaker or cerebral aneurysm clip.\n12. Chronic Kidney Disease (CKD) with eGFR \\\u003C 60.\n13. For women of child-bearing potential (WOCBP): positive urine hCG, trying to achieve pregnancy, or breastfeeding \\[a negative urine pregnancy test is required at screening for women of child-bearing potential\\].\n14. Other medical conditions or severe chronic illnesses that, in the opinion of the Investigator, may present a contraindication to study participation.\n15. Any other condition that, in the opinion of the Investigator, may hinder study compliance or completion of the study schedule of assessments.",{"count":102,"type":19},25,[22],"NAFLD is a growing threat to public health. Currently, there is a significant need for highly effective treatments for NAFLD. Non-obese NAFLD (BMI\\\u003C30kg\u002Fm2) is an increasingly recognized condition, sometimes described as \"lean NAFLD\". Intermittent Fasting (IF) may be uniquely beneficial in non-obese NAFLD. The purpose of this study is to identify non-pharmacologic, lifestyle-based methods of NAFLD treatment within non-obese adults.",[53,106,107,41,28],"Intermittent Fasting","Fatty Liver, Nonalcoholic",[53,106,109,110,111,112,28,41,107],"Non-obese","Diet","Nutrition","Time-restricted","2025-12-10",{"date":115,"type":62},"2025-12-18",{"date":117,"type":62},"2022-02-01",{"date":119,"type":19},"2026-07-31",{"name":121,"class":69},"Massachusetts General Hospital",{"id":123,"slug":4,"hasResults":10,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":129,"enrollmentInfo":130,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":132,"conditions":133,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":146,"locationsCount":148},"100602376","NCT07122700","Evaluation of Non-Invasive Tests for Metabolic Liver Disease","Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) Study 2.0 - An FNIH Biomarkers Consortium Study","NIMBLE","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and availability for the duration of the study\n3. Male or female, aged \\> 18 years and \\\u003C 75 years\n4. Participants must exhibit some manifestations of metabolic dysregulation. Either:\n\nA. Physician-diagnosed T2DM for at least 90 days with HbA1c \\> 6.5 and antidiabetic therapy, if any, stable for at least 90 days prior to screening or B. At least any one of the following six metabolic syndrome criteria \\[6\\]\n\n1\\. body mass index (BMI) of \\> 25 kg\u002Fm2 2. waist circumference: i. \\> 102 cm for men ii. \\> 88.9 cm for women 3. fasting triglyceride concentration \\> 150 mg\u002FdL i. or ongoing treatment with triglyceride lowering medication 4. HDL-cholesterol concentration: i. \\\u003C 40 mg\u002FdL for men ii. \\\u003C 50 mg\u002FdL for women iii. or ongoing treatment with cholesterol lowering medication. 5. fasting glucose concentration \\> 100 mg\u002FdL 6. either semi-recumbent or supine blood pressure systolic \\> 130 mmHg and\u002F or diastolic \\> 85 mmHg i. or ongoing treatment with antihypertensive medication. 5. FIB-4 \\> 1.3 (age \\\u003C 65 years) and \\> 2.0 (age \\> 65 years) 6. Agreement to adhere to Lifestyle Considerations (see section 5.3) throughout study duration\n\nExclusion Criteria:\n\n1. Known history or evidence of other forms of chronic liver disease other than MASLD\u002FMASH including but not limited to viral hepatitis B or C, autoimmune liver disease, primary biliary cholangitis, primary sclerosing cholangitis, Wilson disease, hemochromatosis, drug-induced liver disease, conditions involving bile duct obstructions, liver cancer, past history of HCC or HCC treatment, listed for or history of liver transplantation, prior resection of liver, etc.\n2. Current or past evidence of decompensated liver disease defined by overt ascites that is clinically obvious and requires diuretic therapy, overt encephalopathy requiring therapy or history of variceal hemorrhage\n3. Circulating Alanine aminotransferase (ALT)\\> 5xULN\n4. Ongoing or recent (within the last two years prior to screening) consumption of significantly greater than moderate amounts of alcohol.\n\n   * A standard alcoholic drink is any drink that contains about 14 g of pure alcohol, such as 12 fluid ounces of regular beer 8-10 fluid ounces of malt liquor or flavored malt beverages such as hard seltzer 5 fluid ounces of table wine 3-4 fluid ounces of fortified wine such as sherry or port 2-3 fluid ounces of cordial liqueur or aperitif 1.5 fluid ounces (a single jigger or shot) of brandy, cognac, or distilled spirits such as gin, rum, tequila, vodka, whiskey, etc.\n   * Significantly greater than moderate alcohol consumption is defined as on average over a 2-year period prior to screening:\n\n   Women\n   * \\>1 standard drink per day and\u002For\n   * \\>14 standard drinks per week Men\n   * \\>2 standard drinks per day and\u002For\n   * \\>21 standard drinks per week in men\n\n     * An Alcohol Use Disorders Identification Test (AUDIT) score of 7 or higher\n     * A PEth test score of ≥ 20ng\u002Fml.\n5. In the opinion of the investigator, any contraindications to liver biopsy including but not limited to having significant uncorrected coagulopathy or thrombocytopenia, on chronic anticoagulation with Direct Oral Anticoagulants (DOACs), or on low dose heparin or Warfarin.\n6. Uncontrolled systolic blood pressure \\> 180 mmHg and diastolic blood pressure \\> 120 mmHg at screening. Blood pressure will be obtained after at least 10 minutes of resting in a semi-recumbent or supine position.\n7. Any systemic disease that in the opinion of the investigator precludes inclusion of the patient in the trial\n8. Unable or unwilling to provide informed consent\n9. Unwilling to undergo liver biopsy procedure\n10. Unable or unwilling to comply with requirements for study procedures (such as fasting)\n11. Unable to perform study procedures in the opinion of the investigator\n12. Participants who are unwilling or unable (e.g. due active implants such as pacemaker or having a waist diameter (calculated as: diameter = circumference \u002F π) 70cm, unless a wide-bore MRI machine is available) to undergo MRI procedures.\n13. Pregnancy or planned pregnancy within 4 months of screening.\n14. Participation in another clinical trial within 30 days, or dosing with an investigational agent within 90 days prior to signing the ICF for this study.","75 Years",{"count":131,"type":19},400,"The Non-Invasive Biomarkers for Metabolic Liver Disease (NIMBLE) study is a comprehensive, multi-year collaborative effort to standardize, validate and advance the regulatory qualification of blood- and imaging-based biomarkers to diagnose and stage Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH). MASH is characterized by liver inflammation accompanied by simultaneous fat accumulation in the liver.",[134,135,136,137,27,28,138,139],"Metabolic Associated Fatty Liver Disease","Metabolic Associated Steatotic Liver Disease","Cirrhosis, Liver","NASH","Liver Steatoses","Liver Inflammation","2025-08-07",{"date":142,"type":62},"2025-08-14",{"date":144,"type":62},"2025-05-13",{"date":119,"type":19},{"name":147,"class":69},"Foundation for the National Institutes of Health",4,{"id":150,"slug":4,"hasResults":10,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":154,"eligibilityCriteria":155,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":156,"enrollmentInfo":157,"targetDuration":4,"studyType":20,"phases":159,"briefSummary":161,"conditions":162,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":94},"100488792","NCT05644717","Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH\u002FNAFLD","Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease \u002FNon-Alcoholic Steatohepatitis","Ertu-NASH","Inclusion Criteria:\n\n* Patient able to provide written informed consent\n* Adult males \\& females between 18 to 65 years\n* SGLT2i and insulin naïve patients\n* BMI \\>23 Kg\u002Fm2\n* HbA1C % ≥ 6.5 to 10\n* Documented hepatic steatosis or fatty liver disease on Ultrasound\n* Patient with Type II Diabetes Mellitus\n\nExclusion Criteria:\n\n* History of use of SGLT 2 inhibitors or Glucagon-like peptide (GLP) 1 agonist or insulin; 3 months prior to enrollment in the study.\n* Pioglitazone use in the past 6 months\n* History of vitamin E use (400mg twice daily) 3 months prior to enrollment in the study.\n* History of anti-obesity medication or weight loss procedure (bariatric surgery) use within 3 months prior to enrollment in the study.\n* History of uncontrolled Endocrine disorder (for example uncontrolled hypothyroidism, or that requires frequent dose adjustment, or Cushing's syndrome)\n* History of liver disease including viral hepatitis, auto-immune hepatitis, liver cirrhosis, hepatocellular carcinoma and\u002For HIV\n* History of recurrent UTIs and mycotic infection.\n* Severely ill patients (who have high grade fever, sepsis or acute infection)\n* Pregnant woman, lactating woman or planning pregnancy during study duration\n* History of Drug-induced liver disease (e.g. amiodarone, valproate, tamoxifen, methotrexate, steroids (including homeopathic medicines).\n* History of active substance abuse (cannabinoid-derived substances like heroin, cocaine, amphetamines) based on history and\u002For laboratory tests\n* Alcohol intake 10 - 30 g\u002Fday (three drinks per day) within the previous year\n* Active substance abuse such as acetaminophen over-use, hashish, tobacco products, heroin, cocaine or amphetamines.\n* Severe hepatic impairment ( AST \\& ALT levels \\> 3 times upper limit normal","65 Years",{"count":158,"type":19},164,[160],"PHASE4","Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \\& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)\u002FNon-Alcoholic Steatohepatitis (NASH)",[28,27,163,164,165,166],"Glycemic Control","Body Weight Changes","Waist Circumference","Tolerance","2025-03-19",{"date":169,"type":62},"2025-03-21",{"date":171,"type":62},"2023-03-01",{"date":173,"type":19},"2025-12-01",{"name":175,"class":176},"Getz Pharma","INDUSTRY",{"id":178,"slug":4,"hasResults":10,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":76,"sex":15,"minAge":16,"maxAge":156,"enrollmentInfo":184,"targetDuration":4,"studyType":20,"phases":186,"briefSummary":187,"conditions":188,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":94},"100513186","NCT05962190","Short-term Fat Overfeeding on the Effects of Liver Metabolism","The Effect of Short-term Overconsumption of Specific Dietary Nutrients on Liver and Adipose Tissue Metabolism.","FOS","Inclusion Criteria:\n\n* The participant is willing and able to give informed consent for participation in the study.\n* Male or Female, aged ≥18 or ≤65 years.\n* Body Mass Index ≥19 ≤35 kg\u002Fm2\n* No medical condition or relevant drug therapy that is known to affect liver or adipose tissue metabolism.\n* Weight stable for the previous 3 months\n\nExclusion Criteria:\n\n* The participant is unwilling or unable to give informed consent for participation in the study. - Aged ≤18 or ≥65 years\n* Body Mass Index ≤19 or ≥35kg\u002Fm2\n* Blood haemoglobin \\\u003C135mg\u002FdL for men and \\\u003C120mg\u002FdL for women\n* Donated (or lost) ≥250 ml of blood in the previous two months.\n* On a weight loss diet or have decreased their body weight by \\>5% in the previous 3 months.\n* Have increased their body weight by \\>5% in the previous 3 months.\n* Any metabolic condition or relevant drug therapy\n* Current smoker\n* History of alcoholism or a greater than recommended alcohol intake (\\>30 g of alcohol daily for men and \\>20 g of alcohol daily for women)\n* Haemorrhagic disorders\n* Anticoagulant treatment\n* History of albumin allergy\n* Pregnant or nursing mothers\n* Women prescribed any contraceptive agent or device including oral contraceptives, hormone replacement therapy (HRT) or who have used these within the last 12 months History of severe claustrophobia\n* Presence of metallic implants, pacemakers, or are unwilling to remove any piercings\n* History of an eating disorder or any other psychological condition that may affect the participant's ability to adhere to study intervention\u002Fexperimental diets.",{"count":185,"type":19},26,[22],"Despite work showing the overconsumption of saturated fatty acids (SFA) to be metabolically deleterious, debate continues about whether there is a link between SFA and cardiovascular disease risk. To explore this, we are undertaking a human in vivo parallel-design study, comparing two isocaloric high-fat diets; one enriched with SFA and the other enriched with unsaturated fatty acids (UFAs), to determine the impact of dietary fat composition on postprandial metabolism, liver fat, cardiac fat and cardiac function.",[28,189,190,191],"Cardiac Function","Lipid Disorder","Adiposity","2023-07-18",{"date":194,"type":62},"2023-07-27",{"date":196,"type":62},"2023-02-15",{"date":198,"type":19},"2028-02",{"name":200,"class":69},"University of Oxford",""]